The Y-90 resin microspheres demonstrated a 98.5% best overall objective response rate, with all patients responding to the treatment.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment.

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

KRd as a potential standard-of-care regimen in this hard-to-treat population of high-risk, newly diagnosed multiple myeloma,” said Lisa B. Leypoldt, MD.

Researchers analyzed SOGI data collection practices to determine the factors associated with its prevalence across cancer centers by type and geographic area.

Researchers conducted a retrospective cohort study to assess the predictive value of molecular profiling on thyroid tumor behavior.

The albumin-bilirubin (ALBI) score can independently predict prognosis in post-surgical patients with distal cholangiocarcinoma (dCCA), a form of cholangiocarcinoma (CCA), according to results ...

Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.

A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...

HealthDay News — Women with cardiovascular disease (CVD) have a substantially higher adiposity-associated risk for breast cancer, according to a study published online July 7 in Cancer.

Researchers sought to determine whether SOC pola-R-CHP frontline therapy would be safe and effective in a real-world population of patients with treatment-naïve DLBCL.